Made with FlowPaper - Flipbook Maker
medhealthoutlook.com CRO EDITION AUG 2020 Innovators Medhealth Outlook CRO 2020 Alistair Macdonald Chief Executive Officer Adding Value to Drug Discovery 2Copyright @2020 Medhealth Outlook. All Rights Reserved. The content and images used in the publication should not be reproduced or transmitted in any form or by any means without the prior permission of Medhealth Outlook. Landon Noah Emily Ava Visualizers editor@medhealthoutlook.com Sophia Loren Joe TylerAnthony John Editorial staffs Natasha Jacob Managing Editor DEC 2020 Copyright @ Medhealth Outlook 2020 Subscribe medhealthoutlook.com CROs play a critical role in the drug discovery and development arena and can make a big difference in ensuring good patient recruitment potential. As businesses are depending more on Contract Research Organizations for their drug discovery and development needs, the innovations and technological side of CROs are also on the rise. CROs are dedicated to managing clinical trials and therefore their influential area is in a wide variety of therapeutic areas across the globe. Technologically advanced CROs develop integrated solutions to significantly enhance the efficiency and productivity of clients’ drug and device development programs, providing true transparency across all areas of a study. In parallel, the uses of big data in the life sciences industry continue to explode. Along with the promise of highly effective and precise next-generation therapies, it is revolutionizing collaboration and how strategic partnerships between CROs and sponsors are effectively managed. Such collaborations are increasingly moving to the forefront as organizations work to effectively leverage this wealth of new data and improve analytics to feed the drug development pipeline. CROs-Sponsored-Technology Organizations are also actively working together in driving an approach towards improved and personalized healthcare. The goal is to establish a more data-driven approach towards personalized healthcare while allowing it to demonstrate its applicability to patient-centered outcomes. By creating such collaborations between stakeholders, the industry expands access to the resources needed to navigate and optimize. This type of business model could bring in smoother and sharper drug development while lowering the complexities of delivering the most precise result. Let us hope that the emerging CRO trends in 2021 will be more towards simplified healthcare. Editors Note The Emerging CRO Trend Natasha Jacob Managing Editor Sam Morris Sales sam@medhealthoutlook.com sales@medhealthoutlook.comExpertise Technology Quality Turning our services into your solutions WeareaCROprovidingintegrated, science-driven,productdevelopment servicesthroughoutthedrugdiscovery anddevelopmentprocesstoenablelife sciencecompaniestoachievetheirdrug developmentgoals. CONTACT US TODAY: sales @ frontagelab.com OR VISIT US AT: frontagelab.comStreamlining Bioanalysis with Innovation Unlocking a New Era of Drug Discovery Delivering Flexible and Cost-Efficient CRO Services Streamlining the Nitty- Gritties of Medical Device Development CMIC INC: FRONTAGE LABS ICON NAMSA Jenny Lin COO Dr Song Li, Founder and CEO Dr. Steel Cutler, CEO Dr. Steel Cutler, CEO Adding Value to Drug Discovery 08PAGE NO Alistair Macdonald Chief Executive Officer Innovators Medhealth Outlook 2020 CRO 16 20 28 2420 18 30 LEVERAGING ADVANCED ANALYTICS TO IDENTIFY DRIVERS OF ENDOMETRIOSIS’ ONSET IT’S TIME TO DIVERSIFY THE CLINICAL TRIAL WORKFORCE A CIO’S PERSPECTIVE ON THE PROMISE OF DIGITAL TRANSFORMATION MED INSIGHTS Contents Ewa J. Kleczyk, PhD, Vice President of Advanced Analytics, Symphony Health Jim Kremidas, Executive Director, Association of Clinical Research Professionals Mike Restuccia, CIO of Penn MedicineW ith the rising number of newly discovered diseases and the need for drugs that could deal with these issues, drug research sector is on a constant growth. However, the drug discovery process is complex and critical while clinical development is more crucial with the requirement of huge resources for the best results. Here is where the contract research organizations such as Syneos Health—the only fully integrated biopharmaceutical solutions organization—form a bridge between the discovery and launch of the drug substance for manufacturers. Data research, tests, project management and trials that are run post-approval, clinical and pre-clinical are some of the major activities covered by these CROs that add value to the drug research and development. Created by the merger of two industry leading companies—inVentiv Health and INC Research— Syneos Health is dedicated to bring together about 24,000 clinical and commercial minds with the ability to support customers across more than 110 countries. Under the leadership of Alistair Macdonald, CEO, Syneos Health is purpose-built to accelerate customer performance to address modern drug discovery market realities. Syneos Health is a blend of Contract Research Organization (CRO) and Contract Commercial Organization (CCO). “Our innovative product development model provides opportunities to drive accelerated Adding Value to Drug Discovery Innovators Medhealth Outlook CRO 2020 We continue to execute our strategy to further penetrate large pharma, enhance our small- to mid-sized leadership position and accelerate full service Commercial solutions Alistair Macdonald Chief Executive OfficerNext >